Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages 2574-2581

  Tzelepi, Vassiliki ^a   Efstathiou, Eleni ^a,b   Wen, Sijin ^a   Troncoso, Patricia ^a   Karlou, Maria ^a   Pettaway, Curtis A ^a   Pisters, Louis L ^a   Hoang, Anh ^a   Logothetis, Christopher J ^a   Pagliaro, Lance C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CHROMOGRANIN; CYTOCHROME P450 17; DOCETAXEL; KI 67 ANTIGEN; LEUPRORELIN; MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53; PROTEIN PATCHED; SMOOTHENED PROTEIN; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; STEROID 5ALPHA REDUCTASE 1; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MALE; MULTIPLE CYCLE TREATMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL ADHESION MOLECULES; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TAXOIDS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959288861     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2999     Document Type: Article

References (51)

1. Harris WP, Mostaghel EA, Nelson PS, et al: Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76-85, 2009
2. Bonkhoff H, Berges R: From pathogenesis to prevention of castration resistant prostate cancer. Prostate 70:100-112, 2010
3. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
4. Tannock IF, de Wit R, Berry WR, et al: For the TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
5. Febbo PG, Richie JP, George DJ, et al: Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11:5233-5240, 2005 (Pubitemid 41003711)
6. Beer TM, El-Geneidi M, Eilers KM: Docetaxel (Taxotere®) in the treatment of prostate cancer. Expert Rev Anticancer Ther 3:261-268, 2003 (Pubitemid 36748040)
7. Chi KN, Chin JL, Winquist E, et al: Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 180:565-570, 2008 (Pubitemid 351942412)
8. Gjertson CK, Asher KP, Sclar JD, et al: Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 70:723-727, 2007 (Pubitemid 350030211)
9. Verhagen PC, Schröder FH, Collette L, et al: Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58:261-269, 2010
10. Mathew P, Dipaola R: Taxane refractory prostate cancer. J Urol 178:S36-S41, 2007 (Pubitemid 47211164)
11. Efstathiou E, Troncoso P, Wen S, et al: Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13:1224-1231, 2007 (Pubitemid 46424064)
12. Hellström M, Ranepall P, Wester K, et al: Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer. Br J Urol 79:421-426, 1997 (Pubitemid 28318983)
13. Scattoni V, Montironi R, Mazzucchelli R, et al: Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int 98:54-58, 2006 (Pubitemid 43885504)
14. Mostaghel EA, Page ST, Lin DW, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67:5033-5041, 2007 (Pubitemid 46910214)
15. Efstathiou E, Logothetis CJ: A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res 16:1100-1107, 2010
16. Crook JM, Malone S, Perry G, et al: Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial. Cancer 115:673-679, 2009
17. Liauw SL, Fricano J, Correa D, et al: Doseescalated radiation therapy for intermediate-risk prostate cancer: Patient selection for androgen deprivation therapy using percentage of positive cores. Cancer 115:1784-1790, 2009
18. Sanchez-Ortiz RF, Troncoso P, Babaian RJ, et al: African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer 107:75-82, 2006 (Pubitemid 43939033)
19. Chen ME, Johnston D, Reyes AO, et al: A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 27:1291-1301, 2003 (Pubitemid 37185820)
20. Efstathiou E, Abrahams NA, Tibbs RF, et al: Morphologic characterization of preoperatively treated prostate cancer: Toward a post-therapy histologic classification. Eur Urol 57:1030-1038, 2010
21. Baretton GB, Klenk U, Diebold J, et al: Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80:546-555, 1999 (Pubitemid 29213212)
22. Shi Y, Chatterjee SJ, Brands FH, et al: Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: An in vitro model that corroborates clinical observations. BJU Int 97:170-178, 2006
23. D'Antonio JM, Ma C, Monzon FA, et al: Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate 68:698-714, 2008 (Pubitemid 351632942)
24. Frigo DE, McDonnell DP: Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 7:659-669, 2008 (Pubitemid 351482148)
25. Ohlson N, Wikström P, Stattin P, et al: Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62:307-315, 2005 (Pubitemid 40224136)
26. Hirano D, Okada Y, Minei S, et al: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586-592, 2004 (Pubitemid 38481685)
27. Kojima S, Inahara M, Suzuki H, et al: Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 16:161-167, 2009
28. Pandini G, Mineo R, Frasca F, et al: Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65:1849-1857, 2005
29. Kaplan PJ, Mohan S, Cohen P, et al: The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59:2203-2209, 1999 (Pubitemid 29217686)
30. Chott A, Sun Z, Morganstern D, et al: Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155:1271-1279, 1999 (Pubitemid 29488934)
31. Locke JA, Guns ES, Lubik AA, et al: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415, 2008
32. Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697, 2001 (Pubitemid 33130257)
33. Linja MJ, Savinainen KJ, Saramäki OR, et al: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555, 2001 (Pubitemid 32694958)
34. Planz B, Wang Q, Kirley SD, et al: Androgen responsiveness of stromal cells of the human prostate: Regulation of cell proliferation and keratinocyte growth factor by androgen. J Urol 160:1850-1855, 1998
35. Nakano K, Fukabori Y, Itoh N, et al: Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J 46:405-413, 1999 (Pubitemid 29333948)
36. Le H, Arnold JT, McFann KK, et al: DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 290:E952-E960, 2006
37. Levine AC, Liu XH, Greenberg PD, et al: Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 139:4672-4678, 1998 (Pubitemid 28487786)
38. Niu Y, Altuwaijri S, Lai KP, et al: Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A 105:12182-12187, 2008
39. Stanbrough M, Bubley GJ, Ross K, et al: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825, 2006
40. Montgomery RB, Mostaghel EA, Vessella R, et al: Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castrationresistant tumor growth. Cancer Res 68:4447-4454, 2008
41. 17α) inhibitors in the treatment of prostate cancer: A review. Anticancer Agents Med Chem 9:613-626, 2009
42. Taichman RS, Loberg RD, Mehra R, et al: The evolving biology and treatment of prostate cancer. J Clin Invest 117:2351-2361, 2007 (Pubitemid 47494332)
43. Prins GS, Putz O: Molecular signaling pathways that regulate prostate gland development. Differentiation 76:641-659, 2008 (Pubitemid 352032742)
44. Yang L, Xie G, Fan Q, et al: Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 29:469-481, 2010
45. Shaw A, Bushman W: Hedgehog signaling in the prostate. J Urol 177:832-838, 2007 (Pubitemid 46216347)
46. Karhadkar SS, Bova GS, Abdallah N, et al: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431:707-712, 2004 (Pubitemid 39382619)
47. Efstathiou E, Troncoso P, Wen S, et al: Coordinated modulation of sonic hedgehog (Shh) signaling and androgen receptor (AR) in the prostate tumor microenvironment by chemo-hormonal therapy. J Clin Oncol 25:251s, 2007 (suppl, abstr 5066)
48. Stewart RJ, Panigrahy D, Flynn E, et al: Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165:688-693, 2001 (Pubitemid 32060501)
49. Jain RK, Safabakhsh N, Sckell A, et al: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 95:10820-10825, 1998 (Pubitemid 28413152)
50. Mazzucchelli R, Montironi R, Santinelli A, et al: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45:72-79, 2000
51. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372, 2001 (Pubitemid 32695027)